Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU Topicspharmacology

ICU · pharmacology

ICU Corticosteroids — Comprehensive Pharmacology (Glucocorticoids in Critical Illness)

Also known as Glucocorticoids in ICU · Hydrocortisone septic shock · Dexamethasone ARDS · Methylprednisolone pulses · Stress-dose steroids · ADRENAL trial · APROCCHSS trial · RECOVERY dexamethasone · DEXA-ARDS · Corticosteroid myopathy

ICU corticosteroid pharmacology -- the evidence-based use of glucocorticoids across the full spectrum of critical illness. The four agents every intensivist must master: HYDROCORTISONE (mineralocorticoid-active -- physiological replacement plus refractory septic shock 200 mg/day continuous infusion (ADRENAL) or hydrocortisone plus fludrocortisone (APROCCHSS), adrenal crisis 100 mg IV bolus then 200 mg/24 h), METHYLPREDNISOLONE (ARDS 1 mg/kg/day within 14 days of onset (CIRCI guideline); high-dose IV pulses 1000 mg daily for 3 days in organ-threatening autoimmune disease), DEXAMETHASONE (COVID-19 6 mg once daily up to 10 days (RECOVERY); ARDS 20 mg then 10 mg (DEXA-ARDS); bacterial meningitis 10 mg q6h for 4 days (de Gans); antenatal lung maturation), and PREDNISOLONE (oral -- chronic immunosuppression; PJP adjunct (40 mg BD); CAP; COPD exacerbation 40 mg for 5 days (REDUCE)).

high31 referencesUpdated 26 July 202619 min readSource-verified · Sept 2026

Checked against its sources on 2 Sept 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Adrenal crisis therapy is rapid IV hydrocortisone — 100 mg bolus then 200 mg/24 h (continuous infusion or 50 mg every 6 h) plus 0.9% saline, with fludrocortisone added for primary adrenal insufficiency (Endocrine Society / secondary-adrenal-crisis guidance) — give EMPIRICALLY, do not wait for the cortisol level, and do not substitute dexamethasone
  • Corticosteroid administration is an independent predictor of ICU-acquired paresis (OR 14.90 in a prospective multicentre study of ventilated patients); the historical association with neuromuscular blocking agents is dose- and duration-dependent — minimise exposure to both, especially together
  • Adrenal insufficiency after systemic corticosteroids -- risk rises with dose and duration and no route, dose or duration makes it impossible to exclude (meta-analysis); cessation or dose reduction, infection or surgery can precipitate adrenal crisis (hypotension, hyponatraemia, hyperkalaemia, hypoglycaemia, lethargy). NEVER stop long-term steroids abruptly -- taper and give stress-dose cover
  • Corticosteroids coadministered with NSAIDs is a high-risk characteristic for corticosteroid-induced peptic ulcer (small but highly probable association) — avoid the combination in ICU; use paracetamol/opioids for analgesia in patients on steroids
  • ADRENAL trial: hydrocortisone 200 mg/day did NOT reduce 90-day mortality in ventilated septic shock (27.9% vs 28.8%) — it sped shock resolution (median 3 vs 4 days) and shortened the initial ventilation episode. Reserve for shock REFRACTORY to adequate fluids + vasopressors, NOT all septic shock
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Adrenal crisis therapy is rapid IV hydrocortisone — 100 mg bolus then 200 mg/24 h (continuous infusion or 50 mg every 6 h) plus 0.9% saline, with fludrocortisone added for primary adrenal insufficiency (Endocrine Society / secondary-adrenal-crisis guidance) — give EMPIRICALLY, do not wait for the cortisol level, and do not substitute dexamethasone
  • Corticosteroid administration is an independent predictor of ICU-acquired paresis (OR 14.90 in a prospective multicentre study of ventilated patients); the historical association with neuromuscular blocking agents is dose- and duration-dependent — minimise exposure to both, especially together
  • Adrenal insufficiency after systemic corticosteroids -- risk rises with dose and duration and no route, dose or duration makes it impossible to exclude (meta-analysis); cessation or dose reduction, infection or surgery can precipitate adrenal crisis (hypotension, hyponatraemia, hyperkalaemia, hypoglycaemia, lethargy). NEVER stop long-term steroids abruptly -- taper and give stress-dose cover
  • Corticosteroids coadministered with NSAIDs is a high-risk characteristic for corticosteroid-induced peptic ulcer (small but highly probable association) — avoid the combination in ICU; use paracetamol/opioids for analgesia in patients on steroids
  • ADRENAL trial: hydrocortisone 200 mg/day did NOT reduce 90-day mortality in ventilated septic shock (27.9% vs 28.8%) — it sped shock resolution (median 3 vs 4 days) and shortened the initial ventilation episode. Reserve for shock REFRACTORY to adequate fluids + vasopressors, NOT all septic shock
The one-line exam answer

ICU corticosteroid pharmacology hinges on FOUR agents used at evidence-based doses. HYDROCORTISONE — physiological replacement (15–25 mg/day orally in 2–3 divided doses, Endocrine Society) plus the shock drug: 200 mg/day by continuous infusion (ADRENAL), hydrocortisone plus fludrocortisone (the only septic-shock regimen to reduce 90-day mortality — APROCCHSS), and the CIRCI suggestion of IV hydrocortisone under 400 mg/day for at least 3 days when shock is not responsive to fluid and moderate-to-high-dose vasopressors; adrenal crisis is 100 mg IV bolus then 200 mg/24 h plus 0.9% saline. METHYLPREDNISOLONE — early moderate–severe ARDS (1 mg/kg/day within 14 days of onset, CIRCI) and high-dose IV pulses (1000 mg daily for 3 consecutive days) for organ-threatening autoimmune inflammation. DEXAMETHASONE — COVID-19 requiring oxygen or ventilation (6 mg once daily for up to 10 days, RECOVERY), moderate–severe ARDS (20 mg daily days 1–5 then 10 mg daily days 6–10, DEXA-ARDS), bacterial meningitis (10 mg every 6 h for 4 days, before or with the first antibiotic dose — de Gans), peritumoral cerebral oedema (drug of choice) and antenatal lung maturation (6 mg IM every 12 h for 4 doses). PREDNISOLONE — the oral agent: COPD exacerbation 40 mg daily for 5 days (REDUCE) and the PJP adjunct (prednisone 40 mg BD for 5 days, then 40 mg daily, then 20 mg daily over a 21-day course).[11][1][2][10][12][25][3][4][9][24][26][28][19]

ADRENAL vs APROCCHSS — mortality is not interchangeable

Hydrocortisone 200 mg/day in ventilated septic shock did not reduce 90-day mortality (27.9% vs 28.8%, OR 0.95) but reversed shock faster (median 3 vs 4 days). Hydrocortisone plus fludrocortisone did reduce 90-day mortality (43.0% vs 49.1%, RR 0.88).[1][2]

Overview — exam triangle

For every ICU steroid question: (1) which disease evidence supports steroids, (2) which agent/dose/duration, (3) what harm you monitor (glucose, infection, myopathy, HPA axis after prolonged courses).[1][2]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References31ShowHide
  1. [1]Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock N Engl J Med, 2018.PMID 29347874
  2. [2]Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock N Engl J Med, 2018.PMID 29490185
  3. [3]Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 N Engl J Med, 2021.PMID 32678530
  4. [4]Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial Lancet Respir Med, 2020.PMID 32043986
  5. [5]Meduri GU, Bridges L, Shih MC, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature Intensive Care Med, 2016.PMID 26508525
  6. [6]Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis Ann Intern Med, 2015.PMID 26258555
  7. [7]Chaudhuri D, Sasaki K, Karkar A, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis Intensive Care Med, 2021.PMID 33876268
  8. [8]Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in Severe Community-Acquired Pneumonia N Engl J Med, 2023.PMID 36942789
  9. [9]de Gans J, van de Beek D Dexamethasone in adults with bacterial meningitis N Engl J Med, 2002.PMID 12432041
  10. [10]Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017 Crit Care Med, 2017.PMID 28938253
  11. [11]Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab, 2016.PMID 26760044
  12. [12]Martel-Duguech L, Poirier J, Bourdeau I, et al. Diagnosis and management of secondary adrenal crisis Rev Endocr Metab Disord, 2024.PMID 38411891
  13. [13]Broersen LH, Pereira AM, Jørgensen JO, et al. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis J Clin Endocrinol Metab, 2015.PMID 25844620
  14. [14]Bowley J, Shallish S, Smyth N, et al. Adrenal insufficiency following systemic glucocorticoid therapy: a systematic review and meta-analysis Eur J Intern Med, 2026.PMID 41521083
  15. [15]Schuetz P, Leuppi JD, Bingisser R, et al. Prospective analysis of adrenal function in patients with acute exacerbations of COPD: the Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial Eur J Endocrinol, 2015.PMID 25855628
  16. [16]Chen Cardenas SM, Santhanam P, Morris-Wiseman L, et al. Perioperative Evaluation and Management of Patients on Glucocorticoids J Endocr Soc, 2022.PMID 36545644
  17. [17]Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock N Engl J Med, 2008.PMID 18184957
  18. [18]Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock N Engl J Med, 1987.PMID 3306374
  19. [19]Sistek CJ, Wordell CJ, Hauptman SP Adjuvant corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS patients Ann Pharmacother, 1992.PMID 1421680
  20. [20]Mecoli CA, et al. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience Clin Exp Rheumatol, 2017.PMID 28134084
  21. [21]Satoh T, Isozaki O, Suzuki A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition) Endocr J, 2016.PMID 27746415
  22. [22]Furukawa Y, Tanaka K, Isozaki O, et al. Prospective Multicenter Registry-Based Study on Thyroid Storm: The Guidelines for Management From Japan Are Useful J Clin Endocrinol Metab, 2024.PMID 38454797
  23. [23]Chiha M, Samarasinghe S, Kabaker AS Thyroid storm: an updated review J Intensive Care Med, 2015.PMID 23920160
  24. [24]Dixit KS, et al. Optimal Management of Corticosteroids in Patients with Intracranial Malignancies Curr Treat Options Oncol, 2020.PMID 32734428
  25. [25]Mohammadi M, et al. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study Int J Rheum Dis, 2017.PMID 28524639
  26. [26]Chawanpaiboon S, et al. A comparison of 2 doses of antenatal dexamethasone for the prevention of respiratory distress syndrome: an open-label, noninferiority, pragmatic randomized trial Am J Obstet Gynecol, 2024.PMID 37442247
  27. [27]Pecora PG, et al. Corticosteroids and ulcers: is there an association? Ann Pharmacother, 1996.PMID 8826575
  28. [28]Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial JAMA, 2013.PMID 23695200
  29. [29]Wilcox SR Corticosteroids and neuromuscular blockers in development of critical illness neuromuscular abnormalities: A historical review J Crit Care, 2017.PMID 27736708
  30. [30]De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study JAMA, 2002.PMID 12472328
  31. [31]Choo KJ, Simons E, Sheikh A Glucocorticoids for the treatment of anaphylaxis Evid Based Child Health, 2013.PMID 23877942

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousICU Antihypertensive Drugs — ComprehensivepharmacologyNextICU Diuretics Pharmacology — Comprehensive (Loop, Thiazide, K-Sparing, Acetazolamide)pharmacology